Novartis’ study of the drug Afinitor combined with Pfizer’s exemestane was stopped early after positive results. Herve Hoppenot, president of Novartis’ oncology unit, has said the combined treatment will delay chemotherapy treatment in post-menopausal breast cancer sufferers.
Afinitor could well produce an income of $1.5 billion for Novartis, with the drug already approved for kidney cancer treatment and pancreatic cancer treatment in the US. Marketing approval for Afinitor’s use for breast cancer is expected to come at some point during 2012, in order to help breast cancer sufferers worldwide, some 1.38 million in 2008 alone.
Looking for a job in clinical sciences? Start by clicking here, now